MOESM1 of Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma

Additional file 3: Figure S2. of Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow

Rakesh Bam (3449711)
Sharmin Khan (234816)
Wen Ling (234811)
Shelton Randal (3449708)
Xin Li (51274)
Bart Barlogie (234822)
Ricky Edmondson (3449714)
Shmuel Yaccoby (234826)

November 2015

Long-term passaging of MM cells and patient serum as an essential component in the NBM. (A) Flow cyt...

Additional file 1 of Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming

Yuanzheng Liang (13842467)
Haiyan He (1939822)
Weida Wang (772695)
Henan Wang (8850623)
Shaowen Mo (12755084)
Ruiying Fu (11605603)
Xindi Liu (12252509)
Qiong Song (4959706)
Zhongjun Xia (3202539)
Liang Wang (23021)

September 2022

Additional file 1: Supplementary Fig. 1. BM intercellular communication events in patients with NDMM...

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

Moreau, Philippe
van de Donk, Niels WCJ
Miguel, Jesus San
Lokhorst, Henk
Nahi, Hareth
Ben-Yehuda, Dina
Cavo, Michele
Cook, Gordon
Delforge, Michel
Einsele, Hermann
Zweegman, Sonja
Ludwig, Heinz
Driessen, Christoph
Palumbo, Antonio
Facon, Thierry
Plesner, Torben
Dimopoulos, Meletios
Sondergeld, Pia
Sonneveld, Pieter
Mateos, Maria-Victoria

January 2016

Monoclonal antibodies (mAbs) are a recent addition to multiple myeloma (MM) therapies and a number o...

Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma

Saad Z. Usmani
Imran Khan
Christopher Chiu
David Foureau
Lawrence J. Druhan
Katherine Rigby
Tineke Casneuf
A. Kate Sasser

February 2018

Abstract Background Daratumumab, a human CD38 monoclonal antibody that has direct on-tumor and immun...

MOESM1 of Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer

Koji Takada (3721357)
Shinichiro Kashiwagi (305632)
Wataru Goto (3721360)
Yuka Asano (3144573)
Katsuyuki Takahashi (560089)
Tsutomu Takashima (305633)
Shuhei Tomita (312401)
Masahiko Ohsawa (305635)
Kosei Hirakawa (305637)
Masaichi Ohira (656231)

April 2018

Additional file 1: Table S1. Primary antibodies for immunohistochemistry and immunohistochemical eva...

Evaluation of Multiple Myeloma Minimal Residual Disease by using Next Generation Flow in patients undergoing Daratumumab consolidation therapy

PACELLI, PAOLA

January 2022

Multiple Myeloma (MM) is a Plasma Cells (PCs) malignancy characterized by the uncontrolled prolifera...

Additional file 2: of Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus

Suzanne Cole (217727)
Alice Walsh (3524459)
Xuefeng Yin (2102104)
Mihir Wechalekar (5167394)
Malcolm Smith (241397)
Susanna Proudman (838581)
Douglas Veale (424543)
Ursula Fearon (8519)
Costantino Pitzalis (23531)
Frances Humby (84694)
Michele Bombardieri (56532)
Amy Axel (5167388)
Homer Adams (5167391)
Christopher Chiu (543836)
Michael Sharp (5167397)
John Alvarez (3467342)
Ian Anderson (151648)
Loui Madakamutil (4898689)
Sunil Nagpal (1828357)
Yanxia Guo (1600771)

May 2018

Figure S2. Daratumumab has no impact on T cells and monocytes ex vivo. (A) Total number of CD3+ T ce...

Research Article Detection of Minimal Residual Disease by Flow Cytometry for Patients with Multiple Myeloma Submitted to

Isrn Hematology
Autologous Hematopoietic
Stem Cell Transplantation
Rosane Isabel Bittencourt
Lucia Silla

August 2016

which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...

Additional file 1: of CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells

Regina Jitschin (215141)
Domenica Saul (5933270)
Martina Braun (3843)
Sehmus Tohumeken (5933273)
Simon Völkl (5933276)
Roman Kischel (787148)
Michael Lutteropp (5933279)
Cedric Dos Santos (5933282)
Andreas Mackensen (18003)
Dimitrios Mougiakakos (149682)

November 2018

Table S1. Fluorochrome-coupled antibodies and/or chemical dyes for flow cytometry. Table S2. AML-der...

Additional file 1 of Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses

Steffen Pfeuffer (3455078)
Leoni Rolfes (10790496)
Timo Wirth (5490884)
Falk Steffen (6446048)
Marc Pawlitzki (6009329)
Andreas Schulte-Mecklenbeck (5337371)
Catharina C. Gross (9572495)
Marcus Brand (206529)
Stefan Bittner (376727)
Tobias Ruck (489271)
Luisa Klotz (163490)
Heinz Wiendl (237353)
Sven G. Meuth (6792518)

September 2022

Additional file 1: Table S1. Antibodies used for flow cytometric analysis of PBMC. Table S2. Tabular...

MOESM7 of Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

Virginie Nägele (4035545)
Andrea Kratzer (4035539)
Gerhard Zugmaier (4035524)
Chris Holland (1899430)
Youssef Hijazi (4035536)
Max Topp (4035527)
Nicola Gökbuget (276599)
Patrick Baeuerle (4035530)
Peter Kufer (239616)
Andreas Wolf (767957)
Matthias Klinger (262712)

May 2017

Additional file 7. Available patient numbers (N) for analysis of cytokine and granzyme B profiles in...

Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference

Noori, Somayya
Verkleij, Christie P.M.
Zajec, Marina
Langerhorst, P.
Bosman, Patricia W.C.
Rijke, Y.B. de
Donk, N.W. van de
Jacobs, J.F.M.

January 2021

Contains fulltext : 241442.pdf (Publisher’s version ) (Open Access

New developments in the treatment of multiple myeloma – clinical utility of daratumumab

McEllistrim C
Krawczyk J
O'Dwyer ME

April 2017

Cian McEllistrim,1 Janusz Krawczyk,1 Michael E O’Dwyer1,2 1Department of Hematology, Universit...

Additional file 3: of A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

Wan-Hong Zhao (6109325)
Jie Liu (15128)
Bai-Yan Wang (6109328)
Yin-Xia Chen (6109331)
Xing-Mei Cao (6109334)
Yun Yang (417125)
Yi-Lin Zhang (276278)
Fang-Xia Wang (6109337)
Peng-Yu Zhang (6109340)
Bo Lei (310282)
Liu-Fang Gu (6109343)
Jian-Li Wang (1631008)
Nan Yang (305078)
Ru Zhang (431993)
Hui Zhang (7197)
Ying Shen (48310)
Ju Bai (6109346)
Yan Xu (14594)
Xu-Geng Wang (6109349)
Rui-Li Zhang (675458)
Li-Li Wei (6109352)
Zong-Fang Li (540741)
Zhen-Zhen Li (4046321)
Yan Geng (268097)
Qian He (248656)
Qiu-Chuan Zhuang (6109355)
Xiao-Hu Fan (6109358)
Ai-Li He (6109361)
Wang-Gang Zhang (6109364)

December 2018

Relationship between BCMA expression and clinical response, progression-free survival, and overall s...

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma

Michael Chrobok (6238610)

January 2019

FCS files from detailed phenotyping for paper " Infectious complications and NK cell depletion follo...

Additional file 3: Figure S2. of Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow

Rakesh Bam (3449711)
Sharmin Khan (234816)
Wen Ling (234811)
Shelton Randal (3449708)
Xin Li (51274)
Bart Barlogie (234822)
Ricky Edmondson (3449714)
Shmuel Yaccoby (234826)

November 2015

Long-term passaging of MM cells and patient serum as an essential component in the NBM. (A) Flow cyt...

Additional file 1 of Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming

Yuanzheng Liang (13842467)
Haiyan He (1939822)
Weida Wang (772695)
Henan Wang (8850623)
Shaowen Mo (12755084)
Ruiying Fu (11605603)
Xindi Liu (12252509)
Qiong Song (4959706)
Zhongjun Xia (3202539)
Liang Wang (23021)

September 2022

Additional file 1: Supplementary Fig. 1. BM intercellular communication events in patients with NDMM...

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

Moreau, Philippe
van de Donk, Niels WCJ
Miguel, Jesus San
Lokhorst, Henk
Nahi, Hareth
Ben-Yehuda, Dina
Cavo, Michele
Cook, Gordon
Delforge, Michel
Einsele, Hermann
Zweegman, Sonja
Ludwig, Heinz
Driessen, Christoph
Palumbo, Antonio
Facon, Thierry
Plesner, Torben
Dimopoulos, Meletios
Sondergeld, Pia
Sonneveld, Pieter
Mateos, Maria-Victoria

January 2016

Monoclonal antibodies (mAbs) are a recent addition to multiple myeloma (MM) therapies and a number o...

Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma

Saad Z. Usmani
Imran Khan
Christopher Chiu
David Foureau
Lawrence J. Druhan
Katherine Rigby
Tineke Casneuf
A. Kate Sasser

February 2018

Abstract Background Daratumumab, a human CD38 monoclonal antibody that has direct on-tumor and immun...

MOESM1 of Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer

Koji Takada (3721357)
Shinichiro Kashiwagi (305632)
Wataru Goto (3721360)
Yuka Asano (3144573)
Katsuyuki Takahashi (560089)
Tsutomu Takashima (305633)
Shuhei Tomita (312401)
Masahiko Ohsawa (305635)
Kosei Hirakawa (305637)
Masaichi Ohira (656231)

April 2018

Additional file 1: Table S1. Primary antibodies for immunohistochemistry and immunohistochemical eva...

Evaluation of Multiple Myeloma Minimal Residual Disease by using Next Generation Flow in patients undergoing Daratumumab consolidation therapy

PACELLI, PAOLA

January 2022

Multiple Myeloma (MM) is a Plasma Cells (PCs) malignancy characterized by the uncontrolled prolifera...

Additional file 2: of Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus

Suzanne Cole (217727)
Alice Walsh (3524459)
Xuefeng Yin (2102104)
Mihir Wechalekar (5167394)
Malcolm Smith (241397)
Susanna Proudman (838581)
Douglas Veale (424543)
Ursula Fearon (8519)
Costantino Pitzalis (23531)
Frances Humby (84694)
Michele Bombardieri (56532)
Amy Axel (5167388)
Homer Adams (5167391)
Christopher Chiu (543836)
Michael Sharp (5167397)
John Alvarez (3467342)
Ian Anderson (151648)
Loui Madakamutil (4898689)
Sunil Nagpal (1828357)
Yanxia Guo (1600771)

May 2018

Figure S2. Daratumumab has no impact on T cells and monocytes ex vivo. (A) Total number of CD3+ T ce...

Research Article Detection of Minimal Residual Disease by Flow Cytometry for Patients with Multiple Myeloma Submitted to

Isrn Hematology
Autologous Hematopoietic
Stem Cell Transplantation
Rosane Isabel Bittencourt
Lucia Silla

August 2016

which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...

Additional file 1: of CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells

Regina Jitschin (215141)
Domenica Saul (5933270)
Martina Braun (3843)
Sehmus Tohumeken (5933273)
Simon Völkl (5933276)
Roman Kischel (787148)
Michael Lutteropp (5933279)
Cedric Dos Santos (5933282)
Andreas Mackensen (18003)
Dimitrios Mougiakakos (149682)

November 2018

Table S1. Fluorochrome-coupled antibodies and/or chemical dyes for flow cytometry. Table S2. AML-der...

Additional file 1 of Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses

Steffen Pfeuffer (3455078)
Leoni Rolfes (10790496)
Timo Wirth (5490884)
Falk Steffen (6446048)
Marc Pawlitzki (6009329)
Andreas Schulte-Mecklenbeck (5337371)
Catharina C. Gross (9572495)
Marcus Brand (206529)
Stefan Bittner (376727)
Tobias Ruck (489271)
Luisa Klotz (163490)
Heinz Wiendl (237353)
Sven G. Meuth (6792518)

September 2022

Additional file 1: Table S1. Antibodies used for flow cytometric analysis of PBMC. Table S2. Tabular...

MOESM7 of Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

Virginie Nägele (4035545)
Andrea Kratzer (4035539)
Gerhard Zugmaier (4035524)
Chris Holland (1899430)
Youssef Hijazi (4035536)
Max Topp (4035527)
Nicola Gökbuget (276599)
Patrick Baeuerle (4035530)
Peter Kufer (239616)
Andreas Wolf (767957)
Matthias Klinger (262712)

May 2017

Additional file 7. Available patient numbers (N) for analysis of cytokine and granzyme B profiles in...

Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference

Noori, Somayya
Verkleij, Christie P.M.
Zajec, Marina
Langerhorst, P.
Bosman, Patricia W.C.
Rijke, Y.B. de
Donk, N.W. van de
Jacobs, J.F.M.

January 2021

Contains fulltext : 241442.pdf (Publisher’s version ) (Open Access

New developments in the treatment of multiple myeloma – clinical utility of daratumumab

McEllistrim C
Krawczyk J
O'Dwyer ME

April 2017

Cian McEllistrim,1 Janusz Krawczyk,1 Michael E O’Dwyer1,2 1Department of Hematology, Universit...

Additional file 3: of A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

Wan-Hong Zhao (6109325)
Jie Liu (15128)
Bai-Yan Wang (6109328)
Yin-Xia Chen (6109331)
Xing-Mei Cao (6109334)
Yun Yang (417125)
Yi-Lin Zhang (276278)
Fang-Xia Wang (6109337)
Peng-Yu Zhang (6109340)
Bo Lei (310282)
Liu-Fang Gu (6109343)
Jian-Li Wang (1631008)
Nan Yang (305078)
Ru Zhang (431993)
Hui Zhang (7197)
Ying Shen (48310)
Ju Bai (6109346)
Yan Xu (14594)
Xu-Geng Wang (6109349)
Rui-Li Zhang (675458)
Li-Li Wei (6109352)
Zong-Fang Li (540741)
Zhen-Zhen Li (4046321)
Yan Geng (268097)
Qian He (248656)
Qiu-Chuan Zhuang (6109355)
Xiao-Hu Fan (6109358)
Ai-Li He (6109361)
Wang-Gang Zhang (6109364)

December 2018

Relationship between BCMA expression and clinical response, progression-free survival, and overall s...

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma

Michael Chrobok (6238610)

January 2019

FCS files from detailed phenotyping for paper " Infectious complications and NK cell depletion follo...

Additional file 3: Figure S2. of Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow

Rakesh Bam (3449711)
Sharmin Khan (234816)
Wen Ling (234811)
Shelton Randal (3449708)
Xin Li (51274)
Bart Barlogie (234822)
Ricky Edmondson (3449714)
Shmuel Yaccoby (234826)

November 2015

Long-term passaging of MM cells and patient serum as an essential component in the NBM. (A) Flow cyt...

Additional file 1 of Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming

Yuanzheng Liang (13842467)
Haiyan He (1939822)
Weida Wang (772695)
Henan Wang (8850623)
Shaowen Mo (12755084)
Ruiying Fu (11605603)
Xindi Liu (12252509)
Qiong Song (4959706)
Zhongjun Xia (3202539)
Liang Wang (23021)

September 2022

Additional file 1: Supplementary Fig. 1. BM intercellular communication events in patients with NDMM...

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

Moreau, Philippe
van de Donk, Niels WCJ
Miguel, Jesus San
Lokhorst, Henk
Nahi, Hareth
Ben-Yehuda, Dina
Cavo, Michele
Cook, Gordon
Delforge, Michel
Einsele, Hermann
Zweegman, Sonja
Ludwig, Heinz
Driessen, Christoph
Palumbo, Antonio
Facon, Thierry
Plesner, Torben
Dimopoulos, Meletios
Sondergeld, Pia
Sonneveld, Pieter
Mateos, Maria-Victoria

January 2016

Monoclonal antibodies (mAbs) are a recent addition to multiple myeloma (MM) therapies and a number o...

MOESM1 of Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma

Abstract

Extracted data

MOESM1 of Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma

Abstract

Extracted data

Related items

Related items